At the moment, the only other approved medicine for SMA is Biogen’s blockbuster SMA treatment Spinraza (nusinersen), so it will be interesting to see if Zolgensma’s availability has impacted ...

Along with Zolgensma – which made its debut in 2019 – Biogen has had approval to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...

Biogen’s applications for the higher dose regimen of SMA drug Spinraza are now under review in the US and Europe.

However, the eligible patient population indicated for Novartis' Zolgensma is limited ... s once-quarterly IT administration of Spinraza (nusinersen) and Roche’s once-daily Evrysdi (risdiplam).

Currently three treatments are available for SMA patients – Onasemnogene abeparvovec-xioi (Zolgensma) a gene therapy for treating children below two years of age, Nusinersen (Spinraza ...

JEWELFISH (NCT03032172) is an open-label study of risdiplam in 174 patients with SMA who previously received RG7800 (RO6885247), nusinersen (SPINRAZA®), olesoxime or onasemnogene abeparvovec ...